Sun Pharmaceutical aims revenue growth of 18-20% for current fiscal

29 May 2013 Evaluate

Sun Pharmaceutical Industries, country’s third largest drug maker by sales aims revenue growth of 18-20% for the current fiscal year ending March 2014. It is planning to invest Rs 800 crore on capital expenditure and file about 25 generic drug applications for approval in the United States.

The entity’s sales rose by 31.8% in the March quarter over the year-ago period to Rs 3,071.5 crore, and its gross margin rose as material costs increased by only 7.9%. While, the profit was boosted by higher other income and lower tax rate at 13.8%.

Sun Pharma Inds. Share Price

1794.30 -12.60 (-0.70%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×